Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1569-1578

  Ning, Shoucheng ^a   Nemeth, Jeffrey A ^b   Hanson, Rebecca L ^b   Forsythe, Kevin ^a   Knox, Susan J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; CNTO 95; FIBRONECTIN; INTEGRIN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VITRONECTIN; INTEGRIN; MONOCLONAL ANTIBODY CNTO 95;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION (PATHOLOGY); RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; TIME; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRINS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; RADIOIMMUNOTHERAPY; TIME FACTORS;

EID: 49849104203     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0288     Document Type: Article

References (32)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
2. Wachsberger P, Burd R, Dicker AP. Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am 2004;18:1039-57.
3. Shintani S, Li C, Mihara M, et al. Anti-tumor effect of radiation response by combined treatment with angiogenesis inhibitor, TNP-470, in oral squamous cell carcinoma. Oral Oncol 2006;42:66-72.
4. Trikha M, Zhou Z, Nemeth JA, et al. CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004;110:326-35.
5. Martin PL, Jiao Q, Cornacoff J, et al. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti- αv integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res 2005;11:6959-65.
6. v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 2007;13:2128-35.
7. Ning S, Laird D, Cherrington JM, Knox SJ. Anti-angiogenic agents SU5416 and SU6668 increase antitumor effects of fractionated irradiation. Radiat Res 2002;157:45-51.
8. Li L, Wartchow CA, Danthi SN, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 2004;58:1215-27.
9. Ning S, Chen Z, Dirks A, et al. Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis. Radiat Res 2007;168:125-33.
10. Ning S, Shui C, Khan WB, et al. Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998;40:177-87.
11. Ning S, Knox SJ. G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation. Radiat Res 1999;151:659-69.
12. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin N Am 2004;18:991-1006.
13. 3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997;71:320-4.
14. Lipfert L, Haimovich B, Schaller MD, et al. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J Cell Biol 1992;119:905-12.
15. 1-integrin- linked protein kinase. Nature 1996;379:91-6.
16. Hehlgans S, Haase M, Cordes N. Signaling via integrins: implications for cell survival and anticancer strategies. Biochem Biophys Acta 2007;1775:163-80.
17. Stupack DG, Puente XS, Boutsaboualoy S, et al. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001;155:459-70.
18. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
19. Houchen CW, George RJ, Sturmoski MA, Cohn SM. FGF-2 enhances intestinal stem cell survival and its expression induced after radiation injury. Am J Physiol 1999;276:G249-58.
20. Thornton SC, Walsh BJ, Bennett S, et al. Both in vitro and in vivo irradiation are associated with induction of macrophage-derived fibroblast growth factors. Clin Exp Immunol 1996;103:67-73.
21. Ellis LE, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications. Oncologist 2000;5:11-5.
22. Antoniades HN, Galanopoulos T, Neville-Golden L, O'Hara CJ. Malignant epithelial cells in primary human lung carcinoma coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc Natl Acad Sci U S A 1992;89:3942-6.
23. Hermanson M, Funa K, Hartman M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrines and paracrines loops. Cancer Res 1992;52:3213-9.
24. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
25. Torimura T, Sata M, Ueno T, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 1998;29:986-91.
26. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000;5:3-10.
27. Guo W, Giancotti FG. Integrin signaling during tumor progression. Nat Rev Mol Cell Biol 2004;5:816-26.
28. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007;11:69-82.
29. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60.
30. Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67:3560-4.
31. Teicher BA, Depuis NP, Kusumoto T, et al. Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Investig 1995;2:269-76.
32. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-72.